Education and Training
Menu

John (Jack) C. McVey, MD

Jack McVey
Medical School: Cleveland Clinic Lerner College of Medicine Undergraduate: University of Colorado at Boulder

About Dr. McVey

Jack is a general surgery resident. He graduated from the University of Colorado at Boulder with a Bachelor of Arts in Molecular, Cellular and Developmental Biology. He then received his medical degree from the Cleveland Clinic Lerner College of Medicine. He plans to peruse a career in academic surgical oncology.

Education

2016 - 2021
MD - Cleveland Clinic Lerner College of Medicine

2011 - 2015
University of Colorado Boulder

Societies

  • American Association for Cancer Research
  • American College of Surgeons

Awards

2022
John and Elizabeth Leonard Family Foundation Scholar in Training Award

2019
Young Investigator Travel Award
American Transplant Congress

2015
Graduation with Highest Honors
University of Colorado at Boulder

2014
Undergraduate Research Award
Howard Hughes Medical Institute

Research

Jack’s research interest has focused on liver and pancreatic tumor immunology. He is currently working with Dr Gregory Beatty studying the liver pro-metastatic niche in pancreatic cancer.

Publications

Manuscripts

  1. Lai MB, Zhang C, Shi J, Johnson V, Khandan L, McVey JC, Klymkowsky MW, Chen Z, Junge HJ. (2017). TSPAN12 is a Norrin co-receptor that amplifies Frizzled4 ligand selectivity and signaling. Cell Rep, 19(13): 2809-2822. doi:10.1016/j.celrep.2017.06.004
  2. Firl DJ, Kimura S, McVey JC, Hashimoto K, Yeh H, Miller CM, Markman JF, Sasaki K, Aucejo FN. (2018). Reframing the approach to patients with hepatocellular carcinoma: Longitudinal assessment with hazard associated with liver transplantation for HCC (HALTHCC) improves ablate and wait strategy. Hepatology, 68(4):1448-1458. doi:10.1002/hep.29907
  3. McVey JC, Sasaki K, Margonis GA, Nowacki AS, Firl DJ, He J, Berber E, Wolfgang C, Miller CM, Weiss M, Aucejo FN. (2019). The impact of resection margin on overall survival for patients with colon cancer liver metastasis varied according to the primary cancer location. HPB (Oxford), 21(6):702-710. doi:10.1016/j.hpb.2018.11.001
  4. Sasaki K, Firl DJ, McVey JC, Schold JD, Iuppa G, Diago Uso T, Fujiki M, Aucejo FN, Quintini C, Eghetsad B, Miller CM, Hashimoto K. (2019). Elevated risk of split-liver grafts in adult liver transplantation: Statistical artifact or nature of the beast? Liver Transpl, 25(5):741-751. doi:10.1002/lt.25409
  5. Margonis GA, Amini N, Andreatos N, Sasaki K, McVey JC, Mirza MB, Warner S, Buettner S, Barbon C, Wang J, Pulvirenti A, Angelou A, Kamphues C, Antoniou E, Pikoulis E, Pawlik TM, Kaczirek K, Poultsides G, Wagner D, Endo I, Imai K, Aucejo F, Kreis ME, Wolfgang CL, Weiss MJ. (2019).  KRAS mutational status impacts pathologic response to pre-hepatectomy chemotherapy: a study from the International Genetic Consortium for Liver Metastases. HPB (Oxford), 21(11):1527-1534. doi:10.1016/j.hpb.2019.03.368
  6. Firl DJ, Sasaki K, McVey JC, Hupertz V, Radhakrishnan K, Fujiki M, Eghtesad B, Miller CM, Quintini C, Hashimoto K. (2019). Improved survival following living donor liver transplantation for pediatric acute liver failure: Analysis of 20 years of US National Registry Data.  Liver Transpl, 25(8):1241-1250. doi:10.1002/lt.25499
  7. Sasaki K, McVey JC, Firl DJ, Andreatos N, Moro A, Coromina Hernandez L, Matsushima H, Teresa DU, Fujiki M, Aucejo FN, Quintini C, Kwon CD, Eghtesad B, Miller CM, Hashimoto K. (2019). Sufficient hepatic artery flow compensates for poor portal vein flow after liver transplantation in patients with portal vein thrombosis. Clin Transplant, 33(11): e13723. doi:10.1111/ctr.13723
  8. McVey JC, Sasaki K, Firl DJ, Fujiki M, Diago-Uso T, Quintini C, Eghtesad B, Miller CM, Hashimoto K, Aucejo FN. (2019). Prognostication of inflammatory cells in liver transplantation: Is the waitlist neutrophil-to-lymphocyte ratio really predictive of tumor biology? Clin Transplant, 33(12): e13743. doi:10.1111/ctr.13743
  9. Firl DJ, Sasaki K, Agopian VG, Gorgen A, Kimura S, Dumronggittigule W, McVey JC, Iesari S, Mennini G, Vitale A, Finkenstedt A, Onali S, Hoppe-Lotichius M, Vennarecci G, Manzia TM, Nicolini D, Avolio AW, Agnes S, Vivarelli M, Tisone G, Ettorre GM, Otto G, Tsochatzis E, Rossi M, Viveiros A, Cillo U, Markmann JF, Ikegami T, Kaido T, Lai Q, Sapisochin G, Lerut J; European Hepatocellular Cancer Liver Transplant Study Group, Aucejo FN. (2020). Charting the path forward for risk prediction in liver transplant for hepatocellular carcinoma: International validation of HALTHCC among 4,089 patients. Hepatology, 71(2):569-582. doi:10.1002/hep.30838
  10. McVey JC, Sasaki K. (2020). Combination surgery for hepatocellular carcinoma: slashing and burning to improved survival. Ann Transl Med. 8(16):984. doi:10.21037/atm-2020-74
  11. McVey JC, Sasaki K, Firl DJ. (2020). Risk assessment criteria in liver transplantation for hepatocellular carcinoma: proposals to improve transplant oncology. Hepat Oncol, 7(3):Hep26. doi:10.2217/hep-2020-
  12. Heinrich B, Brown ZJ, Diggs LP, Vormehr M, Ma C, Subramanyam V, Rossato U, Ruf B, Walz JS, McVey JC, Wabitsch SF, Fu Q, Yu SJ, Zhang Q, Lai CW, Sahin U, Greten TF. (2021). Steatohepatitis impairs T cell-directed immunotherapies against liver tumors in mice. Gastroenterology, 160(1):331-345 doi:10.1053/j.gastro.2020.09.031
  13. Wabitsch SF, McVey JC, Ma C, Ruf B, Kamenyeva O, Diggs LP, Heinrisch B, Greten TF. (2021). The Covid-19 treatment candidate hydroxychloroquine impairs tumor response to anti-PD1. iScience, 24(1):101990 doi: 10.1016/j.isci.2020.101990
  14. Diggs LP, Ma C, Heinrich B, Ruf B, Cui L, Zhang Q, McVey JC, Wabitsch SF, Heinrich S, Longerich T, Gores G, Rosato U, Lai CW, Subramanyam V, Wang XW, Greten TF. (2021). Combined CD40 agonist and PD1 antagonist impairs tumor growth in murine cholangiocarcinoma. J Hepatol, 74(5):1145-1154 doi: 10.1016/j.jhep.2020.11.037
  15. Wabitsch S, Tandon M, Ruf B, Zhang Q, McCallen JD, McVey JC, Ma C, Green BL, Diggs LP, Heinrich B, Greten TF. (2021). Anti-PD-1 in Combination With Trametinib Suppresses Tumor Growth and Improves Survival of Intrahepatic Cholangiocarcinoma in Mice. Cell Mol Gastroenterol Hepatol, 12(3):1166-1178. doi: 10.1016/j.jcmgh.2021.05.011
  16. Sasaki K, Nair A, Firl DJ, McVey JC, El-Gazzaz G, Diago-Uso T, Fujiki M, Aucejo FN, Quintini C, Kwon CHD, Hashimoto K, Miller C, Eghtesad B. (2021). Should We Be Utilizing More Liver Grafts From Pediatric Donation After Circulatory Death Donors? A National Analysis of the SRTR from 2002 to 2017. Transplantation. 105(9):1998-2006. doi:10.1097/TP.0000000000003458
  17. Sasaki K, Nair A, Firl DJ, McVey JC, Moro A, Diago Uso T, Fujiki M, Aucejo FN, Quintini C, Kwon CD, Hashimoto K, Miller CM, Eghtesad B. (2021). Conditional probability of graft survival in liver transplantation using donation after circulatory death grafts - a retrospective study. Transpl Int, 34(8):1433-1443. doi: 10.1111/tri.13846
  18. Heinrich B, Gertz ME, Schäffer AA, Craig A, Ruf B, Subramanyam V, McVey JC, Diggs LP, Heinrich S, Rosato U, Ma C, Yan C, Hu Y, Zhao Y, Shen TW, Kapoor V, Telford W, Kleiner DE, Stovroff MK, Dhani HS, Kang J, Fishbein T, Wang XW, Ruppin E, Kroemer A, Greten TF, Korangy F. (2022). The tumour microenvironment shapes innate lymphoid cells in patients with hepatocellular carcinoma. Gut, 71(6):1161-1175. doi:10.1136/gutjnl-2021-325288
  19. McVey JC, Green BL, Ruf B, McCallen JD, Wabitsch S, Subramanyam V, Diggs LP, Heinrich B, Greten TF, Ma C. (2022). NAFLD indirectly impairs antigen specific CD8+ T cell immunity against liver cancer in mice. iScience, 25(2):103847. doi:10.1016/j.isci.2022.103847 
  20. Wabitsch S, McCallen JD, Kamenyeva O, Ruf B, McVey JC, Kabat J, Walz JS, Rotman Y, Bauer KC, Craig AJ, Pouzolles M, Phadke I, Catania V, Green BL, Fu C, Diggs LP, Heinrich B, Wang XW, Ma C, Greten TF. (2022). Metformin treatment rescues CD8(+) T cell response to immune checkpoint inhibitor therapy in mice with NAFLD. J Hepatol, 77(3):748-760. doi:10.1016/j.jhep.2022.03.010
  21. Ma C, Fu Q, Diggs LP, McVey JC, McCallen J, Wabitsch S, Ruf B, Brown Z, Heinrich B, Zhang Q, Rosato U, Wang S, Cui L, Berzofsky JA, Kleiner DE, Bosco DB, Wu LJ, Lai CW, Rotman Y, Korangy F, Greten TF. (2022). Platelets control liver tumor growth through P2Y12-dependent CD40L release in NAFLD. Cancer Cell, 40(9):986-998 e5. doi:10.1016/j.ccell.2022.08.004
  22. Ma C, McCallen J, McVey JC, Trehan R, Bauer K, Zhang Q, Ruf B, Wang S, Lai CW, Trinchieri G, Berzofsky JA, Korangy F, Greten TF. (2023). CSF-1R+ Macrophages Control the Gut Microbiome-enhanced Liver Invariant NKT Function through IL-18. J Immunol, 211(7):1099-1107. doi:10.4049/jimmunol.2200854
  23. Myojin Y, McCallen JD, Ma C, Bauer KC, Ruf B, Benmebarek MR, Green BL, Wabitsch S, McVey JC, Fu C, Xie C, Greten TF. (2024). Adenosine A2a receptor inhibition increases the antitumor efficacy of anti-PD1 treatment in murine hepatobiliary cancers. Jhep Reports, 6(1):100959. doi:10.1016/j.jhepr.2023.100959
  24. Akabane M, McVey JC, Firl DJ, Kwong AJ, Melcher ML, Kim WR, Sasaki K. (2024). Continuous Risk Score Predicts Waitlist & Post-Transplant Outcomes in Hepatocellular Carcinoma Despite Exception Changes. Clin Gastroenterol Hepatol, 20:S1542-3565(24). doi:10.1016/j.cgh.2024.05.046
  25. Kojima L, Akabane M, Murray M, Fruscione M, Soma D, Snyder A, McVey JC, Firl DJ, Hernandez-Alejandro R, Kubal CA, Markmann JF, Aucejo FN, Tomiyama K, Kimura S, Sasaki K. (2024). Reappraisal of tacrolimus levels post liver transplant for hepatocellular carcinoma: A multicenter study toward personalized immunosuppression regimen. Liver Transpl. [In Press]

Share This Page:
Post Tweet